Related Experiment Video
Updated: Jul 2, 2026

Measuring Biomolecular DSC Profiles with Thermolabile Ligands to Rapidly Characterize Folding and Binding Interactions
Published on: November 21, 2017
Insights into dopaminergic agent cabergoline-induced DNA-destabilisation through spectroscopic, thermodynamic and
Kandasamy Pavithra1, R Durga Priyadharshini1, Vyshnavi Manickam2
1Department of Chemistry, Gandhigram Rural Institute (Deemed to be University), Gandhigram, 624302, India.
None:
Investigating the interaction of therapeutic drugs with DNA is crucial for assessing the possibility of drugs inducing significant DNA alterations when administered. The dopaminergic drug cabergoline's (CBG) interaction with CT-DNA was investigated using multi-spectroscopic, calorimetric, electrophoresis, and computational approaches. The UV-Vis and fluorescence spectral results certified the complexation of CBG with CT-DNA. Though competitive dye displacement assay, viscosity measurements, 1H NMR, KI, and urea studies strongly evidenced the intercalation-type binding mode of CBG, the molecular docking studies disclosed CBG as a groove binder as well as a partial intercalator in the minor and major grooves of DNA, respectively. The significant distortions in the characteristic CD bands of CT-DNA and the results of GEL electrophoresis evidenced the DNA-destabilizing nature of CBG. The profound decrease of 7.3 °C in the Tm of CT-DNA in the presence of CBG reiterated CBG as a DNA destabiliser. The results of metadynamics simulation and binding studies of CBG with single-strand DNA showed that the high affinity of CBG towards ssDNA compared to the dsDNA triggered CBG to destabilise dsDNA. Interestingly, the three different thermodynamic parameters resulted in the calorimetric titration of CBG with CT-DNA, exposing the sequential binding pattern involved in the CBG/CT-DNA complexation and proposing the plausible mechanism of CBG-induced DNA destabilisation.
Related Concept Videos
Drugs that Destabilize Microtubules
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

